In an earlier paper (Freedman, Meisner, and Hill, 1968) we compared the effectiveness of five commercially available bronchodilator aerosols. Three of these-Medihaler Iso Forte, MedihalerDuo, and Prenomiser Plus-contained different doses of isoprenaline; the other two aerosols contained analogues of isoprenaline-orciprenaline in Alupent and isoetharine in Bronchilator. We showed that the maximum response to the preparations containing isoprenaline, as judged by the percentage increase in the forced expiratory volume in one second (FEVy.,) over basal, was approximately linearly related to the logarithm of the dose of isoprenaline. Using this doseresponse line and assuming that the various adjuvants contained in some of the preparations exerted negligible effect on this early peak response, we were able to estimate the doses required to give equal peak response.
In this way, and with the co-operation of the manufacturers, pressurized aerosols of Alupent (A), Bronchilator (B), and Medihaler-Duo (D) were prepared which we would expect to give a peak response equal to that of a single discharge of Medihaler Iso Forte (C). The composition of these modified aerosols, in the dosages given, is shown in Table I .
When comparing the duration of action and unwanted effects of drugs with an immediate action it is clearly desirable to give them in doses which give equal maximum benefit.
METHOD
The four preparations were given to 11 asthmatic patients in random order on separate days. (1) x1 -x.
the absolute increase (2) 1 0O(xt -x) / x. the percentage increase (3) log x, -log xo the logarithmic increase.
There are clinical and statistical arguments both for and against all these measures, but in this case all gave the same qualitative result and results are quoted only for the absolute increase. The visual impression from Fig. 1 is that the adjustment of dose to achieve equal peak responses has been successful and the difference in duration of action of the four treatments then becomes obvious. It is not possible to draw statistical conclusions from these mean responses (Oldham, 1968 that A differs significantly from D and C, but the other differences are not significant at the 5 % level.
The differences in the cardiovascular effects of the drugs are less (Table VI, Minutes after inhalation maximum increase over the basal value, and A, the integrated increment over the first 15 minutes. The average changes after the preparations containing isoprenaline are larger than after orciprenaline or isoetharine, but the F ratios are not significant, the minor changes in heart rate and blood pressure are clinically unimportant, and perhaps scarcely merit an elaborate statistical analysis. The ECGs merely reflected changes in heart rate. In no instance did the complexes vary from the pre-treatment pattern.
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(c) FIG. 2. Mean changes in (a) heart rate, (b) systolic blood pressure and (c) diastolic blood pressure.
DISCUSSION
The work described in this paper is an extension of our earlier work on a comparison of the actions of different bronchodilators (Freedman et al., 1968) . The availability of 20 different makes of pressurized bronchodilator aerosol, all differing in composition or dosage, presents the clinician with an embarrassment of choice. Four of the five preparations used in the comparative trial were used in the present study. The pharmacology of the component drugs (Table I) will be briefly recapitulated. Isoprenaline stimulates all /3-adrenergic receptors. Isoetharine and orciprenaline stimulate predominantly 82-receptors, with some stimulation of 81i-receptors. The action of orciprenaline is claimed to be more persistent than that of isoprenaline. Phenylephrine stimullates a-adrenergic receptors. Its vasoconstrictor action is believed to delay absorption and maintain the action of topically applied /3-stimulators, and to prevent the ventilation-perfusion imbalance that sometimes causes a fall in arterial oxygen saturation after administration of stimulators (Hume, 1970) . Thenyldiamine is an antihistamine. Its effect in naturally occurring asthma is doubtful.
In the previous trial the doses administered were those contained in a single discharge from a pressurized container. The results showed that the level of the peak response was dependent, among other things, on dosage. We concluded that, in comparative experiments of this type, differences in duration of effect were likewise dosedependent, and that, if one wished to compare decay rates of different drugs having similar pharmacological actions, the doses administered must be standardized. The same was true when comparing side-effects and toxic actions. We think that the failure to give equipotential bronchodilator doses has impaired the validity of a number of previously published comparative trials.
From results obtained in our earlier work on relative bronchodilator potencies, we succeeded in the present trial in administering doses that yielded nearly identical peak responses. Our results show that, when inhaled in equipotential peak bronchodilator doses, the action of orciprenaline is more prolonged than that of the three other preparations, whose durations of action do not differ significantly at the 5% level. In the doses given, changes in heart rate and blood pressure were trivial, not clinically important, and there were no ECG changes with any of the preparations.
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